Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.20777 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Diamant Thaçi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Eczema, Hand Dermatoses. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LEO Pharma A/S, Ballerup, Denmark, LEO Pharma.
Abstract (Originalsprache)
Background
Chronic Hand Eczema (CHE) is a prevalent inflammatory skin condition characterized by pain, pruritus and significant impact on patients' quality of life. Delgocitinib cream, a pan‐Janus kinase inhibitor, has shown potential in targeting the key mediators of CHE. To develop a detailed trial drug safety profile, it is vital to assess systemic exposure and bioavailability following repeated drug applications.
Objectives
This analysis aimed to evaluate the systemic exposure and bioavailability of delgocitinib cream 20 mg/g in adults with moderate to severe CHE and compare these parameters with those from oral delgocitinib administration in healthy adults.
Methods
An open‐label, single‐arm, Phase 1 trial (NCT05486117) was conducted involving 16 adults with moderate to severe CHE. Participants applied delgocitinib cream 20 mg/g twice daily for 1 week. Pharmacokinetic sampling was performed on Day (D)1 and D8. Systemic exposure was compared with data from two Phase 1 trials involving oral delgocitinib in healthy adults (1.5–12 mg, NCT05050279, and 1–100 mg, NBX1‐1).
Results
Delgocitinib cream demonstrated minimal systemic exposure, with geometric mean maximum plasma concentration ( C max ) values of 0.50 ng/mL on D1 and 0.46 ng/mL on D8. The geometric mean area under the concentration–time curve from 0 to 12 h (AUC 0–12h ) was 2.5 h*ng/mL on D1 and 3.7 h*ng/mL on D8. No significant accumulation of delgocitinib was observed over time. Systemic exposure with topical application was significantly lower than with oral administration, with a relative bioavailability of 0.6%. Delgocitinib cream was well tolerated, with no reported adverse events during the trial.
Conclusions
Delgocitinib cream shows minimal systemic exposure and is well tolerated in patients with moderate to severe CHE. These findings suggest that no systemic pharmacological effect is expected with the application of delgocitinib cream 20 mg/g to the hands and wrists of patients with moderate to severe CHE. Clinicaltrials.gov (or equivalent) listing: NCT05486117, NCT05050279.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
- Department of Dermatology, Queens University, Peterborough, Ontario, Canada.
- SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada.
- LEO Pharma A/S, Ballerup, Denmark.
- Innovaderm Research, Montreal, Quebec, Canada.
ORCID-Profile: Melinda Gooderham, Robert Bissonnette
Förderung
- LEO Pharma A/S, Ballerup, Denmark
- LEO Pharma
Zitieren
APA
Thaçi, D., Gooderham, M., Lovato, P., Madsen, D. E., Soehoel, A., & Bissonnette, R. (2025). Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20777
Vancouver
Thaçi D, Gooderham M, Lovato P, Madsen DE, Soehoel A, Bissonnette R. Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20777
BibTeX
@article{Thai2025,
author = {Thaçi, Diamant and Gooderham, Melinda and Lovato, Paola and Madsen, Daniel Elenius and Soehoel, Anders and Bissonnette, Robert},
title = {Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.20777}
}
EUVIMED